Understand the source comparison
Peptides for Brain Aging Prevention — Evidence Comparison
Cerebrolysin BDNF upregulation via neurotrophin receptor activation Meta-analysis of 6 RCTs: 2.8-point ADAS-cog improvement vs placebo in 1,275 patients 30ml IV infusion 5 days/week for 4 weeks Strongest evidence for measurable cognitive benefit in mild-to-mod
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF upregulation via neurotrophin receptor activation
- Meta-analysis of 6 RCTs: 2.8-point ADAS-cog improvement vs placebo in 1,275 patients
- 30ml IV infusion 5 days/week for 4 weeks
- Strongest evidence for measurable cognitive benefit in mild-to-moderate neurodegeneration. Requires cumulative dosing above 300ml total
- Dihexa
- Synaptogenesis through HGF receptor binding
- Preclinical models show 7–10× BDNF synaptogenic activity; restores spatial memory in aged rodents within 14 days
- 0.1–1.0 mg/kg orally daily for 7–14 days
- Most potent synaptogenic peptide. Effects persist 4–6 weeks post-treatment, making it suitable for cyclic protocols
- P21
- Caspase-3 inhibition (anti-apoptotic)
- In vitro: 60–75% reduction in neuronal death under oxidative stress
- 1–5mg subcutaneous 3×/week
- Neuroprotective rather than restorative. Prevents ongoing loss from inflammation or ischemia
- Thymalin
- Microglial modulation, cytokine suppression
- 35% reduction in circulating IL-6 in older adults; improved subjective cognitive scores
- 10-day cycle, dose varies by formulation
- Addresses neuroinflammation specifically. Most effective in individuals with elevated inflammatory biomarkers